Pathogenesis of protozoan infections

Baig, Abdul Mannan; Suo, Xun; Liu, Dongyou

doi:10.1016/b978-0-12-818619-0.00091-5

Molecular Medical Microbiology 2024

DOI: 10.1016/b978-0-12-818619-0.00091-5

|View full text |Cite

Pathogenesis of protozoan infections

Abdul Mannan Baig,

Xun Suo,

Dongyou Liu

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Current vaccine candidate of toxoplasmosis

WOLDEGERIMA,

GETACHEW,

MISGANAW

et al. 2024

JLSB

View full text Add to dashboard Cite

Toxoplasma gondii is an intracellular protozoan parasite belonging from the phylum Apicomplexa, known for causing toxoplasmosis. The disease has a global presence, affecting about one-third of the world’s population. The parasite infects various intermediate hosts, including humans and other warm-blooded mammals, with cats serving as the definitive hosts. Its life cycle is complex, featuring a sexual phase in the definitive host and an asexual phase in intermediate hosts. Toxoplasmosis can leads severe neurologic, ocular, and systemic diseases in neonates and immunocompromised individuals. In immunocompetent individuals, the infection is typically asymptomatic, forming dormant tissue cysts in immune-privileged sites such as the muscles and brain. During pregnancy, toxoplasmosis poses significant health risks, potentially causing severe birth defects or miscarriage, and a major concern for immunocompromised hosts. Current control measures are inadequate, highlighting the need for effective vaccines. The initial host defense against T. gondii occurs at the intestinal mucosa, where cytokines and chemokines released by intestinal epithelial cells facilitate the migration of inflammatory cells, including macrophages, neutrophils, and dendritic cells. Developing a vaccine that can enhance this mucosal immunity is crucial for preventing toxoplasmosis. Therefore, the development of vaccines against T.gondii is a promising alternative mechanism to prevent toxoplasmosis. This review aims to present the current status of vaccine candidates against Toxoplasma gondii.

show abstract

Current vaccine candidate of toxoplasmosis

WOLDEGERIMA,

GETACHEW,

MISGANAW

et al. 2024

JLSB

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pathogenesis of protozoan infections

Cited by 1 publication

References 77 publications

Current vaccine candidate of toxoplasmosis

Current vaccine candidate of toxoplasmosis

Contact Info

Product

Resources

About